NCT04546802View on ClinicalTrials.gov

HepATocellular Cancer Hcv Therapy Study

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2023

Conditions
Hepatocellular CarcinomaHepatomaLiver Cell CarcinomaHepatitis C
Interventions
DRUG

Elbasvir / Grazoprevir Oral Tablet

Elbasvir / Grazoprevir

Sponsors

Lead Sponsor

Bayside Health
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Austin Hospital, Melbourne Australia

OTHER

lead

Bayside Health

OTHER_GOV

NCT04546802 - HepATocellular Cancer Hcv Therapy Study | Biotech Hunter | Biotech Hunter